Related Experiment Video
Updated: Mar 31, 2026
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
8.1K
Icariin regulates PRMT/ADMA/DDAH pathway to improve endothelial function.
Hong-Bo Xiao1, Zi-Kui Liu1, Xiang-Yang Lu2
1College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
Pharmacological Reports : PR
|October 21, 2015
Summary
Icariin improves endothelial function by regulating the PRMT/ADMA/DDAH pathway. This study shows icariin reduces oxidative stress and enhances vasorelaxation in ApoE(-/-) mice and HUVECs.
Area of Science:
- Cardiovascular Research
- Endothelial Biology
- Pharmacology
Background:
- Oxidative stress contributes to endothelial dysfunction via the PRMT/ADMA/DDAH pathway.
- Understanding modulators of this pathway is crucial for treating cardiovascular diseases.
Purpose of the Study:
- To investigate the effect of icariin on endothelial function.
- To elucidate the underlying mechanisms involving the PRMT/ADMA/DDAH pathway.
Main Methods:
- ApoE(-/-) mice and primary human umbilical vein endothelial cells (HUVECs) were used.
- Mice received icariin (10 or 30 mg/kg) intragastrically.
- HUVECs were exposed to lysophosphatidylcholine (LPC) with or without icariin.
Main Results:
- Icariin reduced reactive oxygen species, PRMT I expression, and ADMA levels.
- Icariin increased DDAH II expression and activity.
- Endothelium-dependent vasorelaxation was enhanced in icariin-treated ApoE(-/-) mice.
Conclusions:
- Icariin demonstrates a protective effect on endothelial function.
- Icariin modulates the PRMT/ADMA/DDAH pathway to improve endothelial health.
- These findings suggest icariin as a potential therapeutic agent for endothelial dysfunction.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
4.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
562
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562
01:25Adrenergic Agonists: Indirect-Acting Agents
3.0K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
646
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
646
01:09GPCRs Regulate Adenylyl Cylase Activity
8.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K